JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A8219 Gefitinib (ZD1839)
3 Citation

Target: EGFR

Summary: Selective EGFR inhibitor

≥22.34 mg/mL
A8233 DMXAA (Vadimezan)
2 Citation

Target: DT-diaphorases

Summary: Tumnor vascular disrupting agent, apoptosis inducer

insoluble in H2O; insoluble in EtOH; ≥14.1 mg/mL
A2678 SU11274
2 Citation

Target: MET

Summary: C-Met inhibitor,potent and selective

≥28.4 mg/mL
A1670 Enzastaurin (LY317615)
2 Citation

Target: PKC

Summary: PKC beta inhibitor,potent and selective

insoluble in EtOH; insoluble in H2O; ≥8.59 mg/mL
A1882 Cediranib (AZD217)

Target: VEGFR

Summary: VEGFR inhibitor receptor,highly potent

≥22.52 mg/mL
A1987 Ki16425
4 Citation

Target: LPA Receptors

Summary: LPA receptor antagonist

≥23.75 mg/mL
A8300 ZCL278
1 Citation

Target: Cdc42

Summary: Selective Cdc42 inhibitor

≥29.25 mg/mL
A8325 Tivantinib (ARQ 197)
2 Citation

Target: MET

Summary: C-Met inhibitor,non-ATP-competitive

≥18.47 mg/mL
A8364 ARN-509
2 Citation

Target: Androgen Receptor

Summary: Androgen receptor inhibitor

≥23.85 mg/mL
A8449 Indomethacin

Target: COX

Summary: Cox inhibitor